Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Hakeam A. Hakeam"'
Autor:
Hakeam A. Hakeam, Ghadi Askar, Khalid Al Sulaiman, Reem Mansour, Maha M. Al Qahtani, Dana Abbara, Nada Aldhayyan, Nariman Dyab, Liyan Afaneh, Muna Islami, Zainab Al Duhailib
Publikováno v:
Journal of Infection and Public Health, Vol 15, Iss 10, Pp 1081-1088 (2022)
Background: Ceftolozane-tazobactam is an emerging treatment for severe infections caused by multidrug-resistant (MDR) Pseudomonas aeruginosa. However, limited data support its use in bacteremia treatment. This study aimed to assess the effec
Externí odkaz:
https://doaj.org/article/325937fbcb3545ffb4dfcf72d6a70be0
Autor:
Hakeam A. Hakeam, Hala Alsahli, Lama Albabtain, Shahad Alassaf, Zainab Al Duhailib, Sahar Althawadi
Publikováno v:
International Journal of Infectious Diseases, Vol 109, Iss , Pp 1-7 (2021)
Introduction: Antimicrobial treatments for carbapenem-resistant Enterobacteriaceae (CRE) bacteremia are limited, with colistin-based regimens being a primary therapy. Ceftazidime–avibactam is an emerging treatment for various CRE infections. Our st
Externí odkaz:
https://doaj.org/article/9c879baedf2946008be686f77e4adcc3
Publikováno v:
Therapeutic Advances in Infectious Disease, Vol 7 (2020)
High-dose tigecycline therapy is gaining wide acceptance in treating infections caused by multidrug-resistant bacteria. There are no reports of cutaneous hyperpigmentation with the use of high-dose tigecycline. Here we report a case of a woman who de
Externí odkaz:
https://doaj.org/article/d0fb3cc790434cfeb8ea0a1ab1176f43
Autor:
Hakeam A. Hakeam MS Pharm, BCPS, Zainab Al Duhailib MBBS, EDIC, Muhannad Alsemari MBBS, Reem M. Alwaibah PharmD, Madhawi F. Al Shannan PharmD, Munirah Shalhoub PharmD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 26 (2020)
Enoxaparin is indicated for thromboprophylaxis in non-orthopedic surgical patients at a fixed dose of 40 mg daily. According to the US Food and Drug Administration’s enoxaparin prescribing information, this dose exposes low-weight patients (males <
Externí odkaz:
https://doaj.org/article/ef14a509e57a45578aa2989ac1f4a7da
Publikováno v:
Journal of Cardiovascular Pharmacology. 78:867-874
Direct-acting oral anticoagulants (DOACs) vary in bioavailability and sites of absorption in the gastrointestinal tract (GIT). Data on DOAC use after major GIT surgery are limited. The aim of this case series was to report the impact of surgical rese
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82af946c9c282e55fc8743d330eb1b51
https://doi.org/10.1097/fjc.0000000000001142
https://doi.org/10.1097/fjc.0000000000001142
Autor:
Zainab Al Duhailib, Hakeam A. Hakeam, Hala Alsahli, Lama Albabtain, Shahad Alassaf, Sahar Althawadi
Publikováno v:
International Journal of Infectious Diseases, Vol 109, Iss, Pp 1-7 (2021)
Introduction Antimicrobial treatments for carbapenem-resistant Enterobacteriaceae (CRE) bacteremia are limited, with colistin-based regimens being a primary therapy. Ceftazidime-avibactam is an emerging treatment for various CRE infections. This stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90a4f0b7aa517c3fd045e99d43ef42e7
https://doi.org/10.1016/j.ijid.2021.05.079
https://doi.org/10.1016/j.ijid.2021.05.079
Autor:
Sara Alqahtani, Eid Almutairy, Mohammed Khalid, Meshal Alsalhi, Muhannad Alsemari, Zainab Al Duhailib, Saad A Alharbi, Leen Ghonem, Mazin Barry, Ali Alhijji, Hakeam A. Hakeam, Nader M Bin Sheraim
Publikováno v:
Journal of Cardiovascular Pharmacology and Therapeutics
Background:Speculations whether treatment with angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin II receptor blockers (ARB) predisposes to severe coronavirus disease 2019 (COVID-19) or worsens its outcomes. This study assessed the assoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e2f63c55bd66d0b2f30657ce7bdd2fc
https://doi.org/10.1177/1074248420976279
https://doi.org/10.1177/1074248420976279
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Zainab Al Duhailib, Reem M Alwaibah, Madhawi F Al Shannan, Munirah Shalhoub, Muhannad Alsemari, Hakeam A. Hakeam
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis
Clinical and Applied Thrombosis/Hemostasis, Vol 26 (2020)
Clinical and Applied Thrombosis/Hemostasis, Vol 26 (2020)
Enoxaparin is indicated for thromboprophylaxis in non-orthopedic surgical patients at a fixed dose of 40 mg daily. According to the US Food and Drug Administration’s enoxaparin prescribing information, this dose exposes low-weight patients (males <
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64aeaf0c93d2ce460881d31d2b7782e0
https://pubmed.ncbi.nlm.nih.gov/32559127
https://pubmed.ncbi.nlm.nih.gov/32559127
Autor:
Hakeam A. Hakeam, Muhannad Alsemari, Duhailib, Zainab Al, Ghonem, Leen, Alharbi, Saad A., Eid Almutairy, Sheraim, Nader M. Bin, Meshal Alsalhi, Alhijji, Ali, AlQahtani, Sara, Khalid, Mohammed, Barry, Mazin
Supplemental Material, Appendix for Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Blockers With Severity of COVID-19: A Multicenter, Prospective Study by Hakeam A. Hakeam, Muhannad Alsemari, Zainab Al Duhailib, Leen Ghone
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d1994b2b50025194df3de48ffe39a53d
